Strategic Investment By SkylineDx In Cancer Vaccine Company DCPrime

Rotterdam, Leiden 28 October 2014.
SkylineDx, an innovative company in the field of genetic testing for blood cancers, announced today a strategic investment of an undisclosed sum in the Dutch cancer vaccine company DCPrime. The financing is designed to provide DCPrime with funding for the development of its technology platform and to take advantage of the synergies between the cancer companies.

Van Herk Investments, an investor with a long-term investment strategy and shareholder of SkylineDx, supports the investment in DCPrime financially.

The financing arrangement provides DCPrime with funding for the coming years, and will enable DCPrime to continue the development of its DCOne™ technology platform. This platform allows development of vaccines for application in both haematological as well as solid cancers. The collaboration with SkylineDx will particularly strengthen the position of both companies in developing non-toxic treatment alternatives for patients with haematological cancers.

As the strategies of both companies will be closely aligned, DCPrime has replaced the existing supervisory board members with Dharminder Chahal, CEO of SkylineDx. In addition, Marcel Zwaal, CEO of DCPrime, has decided to resign and pursue other career opportunities. Ada Kruisbeek, founder and CSO of DCPrime, will, together with COO Sandra van Wetering, continue to develop the company’s cancer vaccine pipeline.

“I am delighted with the opportunity to invest in DCPrime, a well-managed company with a highly innovative cell platform for cancer treatments and an early but promising product pipeline”, says Dharminder Chahal, CEO of SkylineDx. “The companies will remain operating independently, but will profit from each other’s vast expertise, network, knowledge of blood cancers and possible treatments.” Marcel Zwaal, CEO of DCPrime adds: "We would like to thank DCPrime’s supervisory board members for their excellent support over the past years. We are convinced that, with the backing of SkylineDx, the DCOne™ technology platform will be able to prove its value for patients in the coming years”.

About SkylineDx - Effective and Comprehensive Genetic Testing

SkylineDx develops and markets novel research tools and diagnostic tests using gene signatures for personalized medicine in oncology. In addition, the company continues to work with academic and industrial partners on the development and commercialization of innovative markers and tests, including companion diagnostics

About DCPrime

DCPrime develops off-the-shelf dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne™. DCOne-based dendritic cell vaccines, in some indications loaded with cancer antigens for targeted treatment, will be used as standardized, therapeutic products. The platform combines the power of dendritic cell-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products. DCPrime has successfully completed a Phase I/IIa study in AML and has developed a commercial scale manufacturing process for DCOne-based vaccines.

For further information, questions and interviews please contact:

SkylineDx B.V. – Europe
Rotterdam Science Tower
Marconistraat 16, 18th floor
3029 AK Rotterdam
The Netherlands
Dharminder. S. Chahal
Phone: +31 (0)10 7038410
DCPrime B.V.
BioPartner Leiden
Galileiweg 8
2333 BD Leiden
The Netherlands
Ada M. Kruisbeek
Phone: +31 (0) 6 551 72 158

Help employers find you! Check out all the jobs and post your resume.

Back to news